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The cell surface proteome, the surfaceome, is the interface for
engaging the extracellular space in normal and cancer cells. Here
we apply quantitative proteomics of N-linked glycoproteins to
reveal how a collection of some 700 surface proteins is dra-
matically remodeled in an isogenic breast epithelial cell line
stably expressing any of six of the most prominent prolifera-
tive oncogenes, including the receptor tyrosine kinases, EGFR
and HER2, and downstream signaling partners such as KRAS,
BRAF, MEK, and AKT. We find that each oncogene has some-
what different surfaceomes, but the functions of these proteins
are harmonized by common biological themes including up-
regulation of nutrient transporters, down-regulation of adhesion
molecules and tumor suppressing phosphatases, and alteration
in immune modulators. Addition of a potent MEK inhibitor
that blocks MAPK signaling brings each oncogene-induced sur-
faceome back to a common state reflecting the strong depen-
dence of the oncogene on the MAPK pathway to propagate
signaling. Cell surface protein capture is mediated by covalent
tagging of surface glycans, yet current methods do not afford
sequencing of intact glycopeptides. Thus, we complement the
surfaceome data with whole cell glycoproteomics enabled by a
recently developed technique called activated ion electron trans-
fer dissociation (AI-ETD). We found massive oncogene-induced
changes to the glycoproteome and differential increases in com-
plex hybrid glycans, especially for KRAS and HER2 oncogenes.
Overall, these studies provide a broad systems-level view of
how specific driver oncogenes remodel the surfaceome and the
glycoproteome in a cell autologous fashion, and suggest pos-
sible surface targets, and combinations thereof, for drug and
biomarker discovery.
oncogenes | glycoproteomics | surfaceome | MAPK signaling pathway
The cell surface proteome, or surfaceome, is the main inter-face for cellular signaling, nutrient homeostasis, and cellular
adhesion, and defines immunologic identity. To survive, cancer
cells adjust to promote increased nutrient import, progrowth sig-
naling, and evasion of immunological surveillance, among others
(1). There are some 4,000 different membrane proteins encoded
in the human genome (2, 3), yet antibodies to only about two
dozen cell surface targets have been approved for therapeu-
tic intervention, prompting the need to discover novel tumor
specific antigens (4, 5).
Recent surfaceome studies in an isogenic MCF10A breast
epithelial cell line transformed with oncogenic KRAS have iden-
tified more than two dozen up-regulated surface proteins that
function in a cell autologous fashion to promote increased cell
proliferation, metastasis, metabolic activity, and immunologic
suppression (6–8). Many of the most powerful oncogenes are
linked to KRAS and the MAPK pathway including overactiva-
tion of receptor tyrosine kinases, such as EGFR and HER2, or
mutations in BRAF or RAS (Fig. 1A). It is well known that
these neighboring oncogenes are mutually exclusive in human
tumors. For example, lung cancer patients with oncogenic EGFR
mutations seldom harbor oncogenic KRAS or BRAF mutations
and vice versa (9). Also, recent evidence shows that oncogene
coexpression can induce synthetic lethality or oncogene-induced
senescence, further reinforcing that activation of one oncogene
without the others is preferable in cancer (10, 11).
There is also substantial evidence that cell surface glycosy-
lation is altered in cancer. Incomplete or truncated synthesis,
extended branching, core fucosylation, and sialylation of cell sur-
face glycans are hallmarks of tumor cells, and alter physiological
mechanisms of cell–cell adhesion, communication, and immune
system recognition (12–18). Over the past decade, chemical
glycoproteomics has revealed specific examples of altered gly-
cosylation and heterogeneity of glycans on particular proteins
(19). However, we do not know how expression of different
oncogenes globally alters glycosylation on the individual proteins
at a proteome-wide scale. Very recently, hybrid-type electron
transfer dissociation (ETD) methods, such as activated ion ETD
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Fig. 1. Growth rates and morphologies for MCF10A cells transformed with neighboring proliferative oncogenes in the MAPK pathway. (A) Simplified
signaling schematic relationship of six proliferative oncogenes studied, EGFRL858R, HER2 overexpression, KRASG12V, BRAFV600E, MEKDD, and AKTmyr. (B)
Oncogenic transformation of MCF10A induces diverse cellular morphologies. Note that images are presented in the same order as the schematic in A.
(C) MCF10A cells stably transformed with lentivirus with the different oncogenes grow independent of growth factor. Gray and black lines indicate cellular
growth of MCF10A EV control with and without growth factors, respectively. Cell growth (n = 3) was measured each day for 6 d by CellTiter-Glo luminescent
cell viability assay and normalized to viability on day 1. (D) Suppression of growth for all cell lines by treatment with 100 nM MEK inhibitor (PD0325901) in
the absence of growth factors. MCF10A cells transformed with HER2 appears to be least sensitive to MEKi, followed by KRASG12V and AKTmyr.
(AI-ETD) and ETD with supplemental activation (EThcD),
have emerged as forerunners for glycoproteomic profiling, due
to their ability to generate sequence-informative tandem mass
spectra that link both the peptide backbone and corresponding
glycan modification (20–22). These techniques can provide gran-
ularity to the altered glycosylation states of cell surface proteins
upon oncogenic transformation.
Here we address how neighboring driver oncogenes
(KRASG12V, HER2 overexpression, EGFRL858R, BRAFV600E,
phosphomimetic MEKS218D/S222D, and myristoylated AKT)
stably expressed in a common noncancerous isogenic epithelial
cell alter the surfaceome and glycoproteome. Using cell
surface capture (CSC) (23, 24) and AI-ETD glycoproteomics
(21), we found that each oncogene induced common and
unique sets of up- and down-regulated surface proteins and
associated glycans. These sets of protein revealed common
biological themes, including increased expression of nutrient
transporters and decreased expression of adhesion molecules.
These effects were massively reversed upon inhibition of
the MAPK pathway, emphasizing its central importance in
remodeling the surfaceome. These oncogene-induced surface
proteins highlight targets or combinations to consider for
immunotherapy.
Results
Phenotypic Analysis of Oncogene-Transformed MCF10A Cells.
Tumor biology is highly complex and varies depending on the
cell type of origin, stage, epigenome, stroma, vascularization,
the immune system, and metabolism. We deliberately took a
simplistic reductionist approach to compare how specific pro-
liferative oncogenes alter the cell surface proteome in a cell
autologous fashion by using isogenic cells stably transformed
with different oncogenes. No single cell type, culturing con-
dition, or context is representative of all or even one can-
cer type. For practical reasons, we chose the spontaneously
immortalized breast epithelial MCF10A as our parental cell
line, because it is often used as a neutral starting point for
oncogene studies (25–28). Although MCF10A certainly does
not recapitulate the diversity of mammary cell biology, it is
of epithelial origin like most common tumors; it is nontu-
morigenic, requires growth factors for survival, and does not
harbor gene amplifications or other chromosomal aberrations
typical of advanced cancer cell lines. Our intent is to compare
how neighboring driving oncogenes remodel their surfaceomes
and glycoproteomes in isogenic cells in a cell autologous
fashion.
Lentivirus was used to stably transform MCF10A cells with six
prevalent oncogenes that are neighbors in proliferative signaling:
HER2 overexpression, EGFRL858R, KRASG12V, BRAFV600E, the
phosphomimetic MEKS218D/S222D (MEKDD), and myristoylated
AKT (AKTmyr) (Fig. 1A and SI Appendix, Fig. S1). Remark-
ably, the morphologies of each of the transformed cells varied
from each other when cultured in the absence of growth factors,
indicative of differences in proteomic landscape (Fig. 1B). In
the absence of growth factors, cells transformed with HER2 and
KRASG12V grew to confluence, while cells harboringEGFRL858R,
BRAFV600E, and MEKDD did not reach confluency, indicative
of contact-dependent growth inhibition. Cells transformed with
AKTmyr, which signals through a parallel pathway relative to
the other five oncogenes, had the most dramatic morphology
change, displaying vertically stacked clusters of cells. Unlike the
parental cell line, all of the MCF10A cells stably transformed
with any of the six oncogenes proliferated in the absence of
growth factors to various degrees (Fig. 1C). The HER2- and
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KRASG12V-transformed cells proliferated most rapidly in the
absence of growth factors, and were even comparable to or faster
than the untransformed MCF10A cultured in the presence of
growth factors. The HER2 and KRASG12V cells also lifted off
the plates much more readily than the others, suggesting reduced
adhesion phenotype.
These oncogenes can drive multiple branched pathways, yet
it was previously shown that inhibition of the MAPK pathway
with the potent and selective MEK inhibitor (PD032590, MEKi)
significantly reverses the surfaceome changes of MCF10A cells
transformed with KRASG12V (6). Indeed, MEKi substantially
hampered growth for all cell lines either in the absence or
presence of growth factors (Fig. 1D and SI Appendix, Fig. S2).
Overexpression of HER2 was most resistant to MEKi, followed
byKRASG12V andAKTmyr, whereas cells containingEGFRL858R,
BRAFV600E, or MEKDD were most sensitive to MEKi.
Differential Expression of Oncogene-Induced Surfaceomes in
MCF10A Cells. We next probed how the cell surfaceome is altered
in the oncogene-transformed cells compared to the empty vector
(EV) control. N-glycosylation is present on >85% of cell surface
proteins (29) and can be exploited to capture the N-glycosylated
proteins using a biotin hydrazide enrichment method (CSC) (24,
30). Here, we utilized a CSC protocol coupled with stable iso-
tope labeling by amino acids in cell culture (SILAC) to compare
the surfaceomes from the oncogene-transformed MCF10A cells
to the EV control (SI Appendix, Figs. S3 and S4) (31). We iden-
tified and quantified a total of 654 cell surface proteins across
the six oncogenic cell lines (Fig. 2A). Remarkably, the expres-
sion for 43% of the aggregate surface proteins (280 of 654)
was altered by at least twofold for the oncogene-transformed
cell lines relative to EV control, reflecting significant remodel-
ing of the surfaceomes. In each of the six datasets, we observed
at least twofold changes for 100 to 150 different surface pro-
teins (Fig. 2A and SI Appendix, Fig. S5 A–F); these changes
were evenly split between up- and down-regulated sets, reflecting
bidirectional remodeling (SI Appendix, Fig. S6). Many of the dif-
ferentially expressed proteins overlapped, but each cell line had a
substantial number of uniquely differentially regulated proteins,
presumably resulting from slight differences in signaling between
each oncogene. Although it is well known that correlations
between protein and RNA levels are not often strongly corre-
lated (6, 32, 33), we were prompted to determine whether the
most common changes were observed in previous studies. Down-
regulation of BCAM and NRCAM transcription, in particular,
was found in patient samples harboring the same oncogenic sig-
natures in a number of cancers types of epithelial origin (Fig. 2 B
andC). Using the 17 TCGA provisional dataset from The Cancer
Genome Atlas (TCGA) with carcinoma (epithelial origin) anno-
tation (34), activating oncogenic signature was defined as G12 or
Q61 mutation in KRAS, L858 or amplification of EGFR, V600E
mutation in BRAF, or amplification of HER2. Transcriptional
up-regulation of MME, however, was not found in any of the
dataset searched, suggesting regulation at the translational level
or additional factors at play.
At a global level, there were greater similarities between
particular oncogenes. For example, cells harboring KRASG12V
and HER2 clustered more closely together (cluster 1), and
those containingBRAFV600E,AKTmyr, EGFRL858R, andMEKDD
clustered together (cluster 2) as seen either in the upset plot
(Fig. 2A) or a heatmap with hierarchical clustering (Fig. 2D).
The Pearson correlation coefficients were also higher within
rather than across the two clusters (SI Appendix, Fig. S7A). One
of the striking findings was the up-regulation of HER2 expres-
sion in the KRASG12V-transformed cells but not in cluster 2
transformed cells (SI Appendix, Fig. S8), which may help to
explain the stronger similarity in oncogene-induced surfaceomes
between the HER2 and KRASG12V cell lines. This same analy-
sis also showed striking compensating regulation, where HER2
is down-regulated in the EGFR oncogene-expressing cell line.
Despite detailed differences at the individual target level,
these harmonized into common biological processes when
viewed by Gene Set Enrichment Analysis (GSEA) (Fig. 2E).
For example, glycosylation and carbohydrate metabolism were
similarly altered features for all of the oncogenes (Fig. 2F),
consistent with numerous reports that altered glycosylation cor-
relates with the development and progression of cancer (35–37).
In addition, we see strong down-regulation of proteins involved
in differentiation and adhesion, reflecting cell attachment and
migration (SI Appendix, Fig. S9A). There were also large changes
in some cell surface phosphatases involved in down-regulation
of receptor tyrosine kinases (SI Appendix, Fig. S9B). These spe-
cific heatmaps reinforce the general division between cluster 1
and cluster 2. Due to the complexity of this data type, a data
browser was made to view each individual gene set identified
(https://wellslab.ucsf.edu/oncogene surfaceome).
MEK Inhibition Induces Common Surfaceome Changes. The
MAPK pathway is a central driver of cell proliferation and has
been a major therapeutic target in cancer. Indeed, MEKi signif-
icantly impedes the growth of all of the oncogene-transformed
cells either in the absence (Fig. 1D) or presence of growth fac-
tors (SI Appendix, Fig. S2). To determine how MEKi alters the
surfaceome of the oncogene-transformed cells, we compared the
proteomic landscape of each oncogenic cell line in the presence
and absence of MEKi. The proteomics dataset identified and
quantified a total of 772 proteins, including an intersection of 492
proteins with the EV dataset discussed above, for a total of 934
proteins quantified between the two experiments. (Fig. 3 A–C).
In large measure, MEKi reversed the effects of the oncogenes
and remarkably induced a more common state between all of
the cell lines, including the EV control. For example, in con-
trast to the uninhibited datasets where 43% of proteins were
differentially regulated by more than twofold in the oncogene-
expressing cells, only 17% of the proteins (129 of 772) were
altered by more than twofold in the presence of MEKi (Fig. 3A
and SI Appendix, Fig. S6A). These changes were mostly bidi-
rectional, except for BRAF and EGFR cell lines where MEK
inhibition has skewness >1 or <−1 (SI Appendix, Fig. S6B).
Of the proteins detected, 18 proteins were commonly changed
across all oncogenes, as opposed to 3 in the absence of MEK
inhibition (Fig. 3A and SI Appendix, Fig. S5 G–M). The similar-
ity can be seen by hierarchical clustering of the MEKi datasets
showing common changes across all cell lines (Fig. 3B). The
Pearson correlation between the six oncogenes and the untrans-
formed control were also higher, in general (SI Appendix, Fig.
S7B). MEKi in KRASG12V and HER2 are still most closely cor-
related. GSEA of the MEKi data indicated a general common
phenotypic reversal with down-regulation of membrane trans-
porters, metabolism, and up-regulation of cell adhesion proteins
consistent with a decrease in cancer-associated phenotypes such
as cellular proliferation and metastasis (Fig. 3C and SI Appendix,
Fig. S9 C and D).
Integration of the oncogenic transformation and MEKi
datasets show 20 protein targets symmetrically flip from being
significantly up- to down-regulated or visa versa in at least three
of the cell lines, suggesting that the expression of these proteins
is strongly dependent on the MAPK signaling pathway (Fig. 3D).
One such target, PODXL, appears to be stringently regulated
by the MAPK pathway. Using the same informatics approaches
described above, transcription of PODXL was also found to
be strongly up-regulated in several cancer types of epithelial
origin (Fig. 3E). Additionally, 75 targets that were markedly
up- or down-regulated revert to a median level of expression
upon treatment with MEKi in at least three cell lines (Fig. 3F).
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Fig. 2. Proliferative oncogenes cause large changes in the surfaceome that are diverse in detail but have common functional themes. (A) Many differentially
regulated proteins are unique to each cell line, and only three proteins were commonly up- or down-regulated among all six oncogene-transformed cell
lines when compared to the EV control. In the vertical bar graph, up-regulated proteins (red) are indicated by the upward bars, and down-regulated
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Interestingly, there were a handful of oncogene-induced targets
that are further up-regulated upon MEKi, such as MME, sug-
gesting they are maintained by circuitous pathways outside of
MAPK (MEKi independent). Overall, the six oncogenes cause
profound changes to the surfaceome that alter common biolog-
ical processes, which can be largely blunted by inhibition of the
MAPK pathway.
Oncogenes Induce Large Changes to the Glycoproteome. Glyco-
sylation has long been known as a biomarker for cancer (35, 38–
40), and our GSEA data show systematic up-regulation of pro-
teins involved in glycosylation, especially in cluster 2 (Fig. 2E).
We thus sought to identify the N-glycosylation modifications on
specific membrane proteins for the six oncogene-transformed
cell lines to compare among themselves and with the EV control.
For maximal coverage, we enriched the glycoproteomes using
the lectin ConA and hydrophilic interaction liquid chromatogra-
phy (HILIC) that provide a complementary means for capturing
high-mannose-type and complex-type glycans, respectively (41,
42). We processed the N-glycoproteomes in biological triplicate
using liquid chromatography - tandem mass spectrometry (LC-
MS/MS) and coupled with AI-ETD (SI Appendix, Fig. S10) (43).
AI-ETD fragmentation combines radical-driven dissociation and
vibrational activation and was recently shown to afford robust
fragmentation of intact glycopeptides (21). Spectral assignments
were made using the Byonic search engine (44); glycopeptides
that were not identified across each of the three biological
replicates for each cell line were removed (SI Appendix, Fig. S11).
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Fig. 3. Inhibition of MEK led to similar perturbations of the surfaceome regardless of oncogenic transformation. (A) The majority of differentially regulated
surface proteins were either completely unique (highlighted in yellow) or completely common (bar 3) to all seven cell lines upon MEK inhibitor treatment
compared to control treatment. In the vertical bar graph, up-regulated proteins (red) are indicated by the upward bars, and down-regulated proteins
(blue) are indicated by the downward bars. The specific overlapping groups are indicated by the black solid dots below each bar. The total number of
differentially regulated proteins for each cell line are indicated by the horizontal bar graph. Up-regulated (red) and down-regulated (blue) proteins are
defined as log2(fold change [FC]) > 1 and P value < 0.05. (B) Hierarchal clustering of surfaceome changes shows MEK inhibition treatment affected each
cell line similarly. (C) Top 30 enriched gene sets identified by GSEA of the proteomics dataset using Gene Ontology terms show similarities between all
cell lines, indicating that unique changes could be functionally redundant. Positive normalized effect size (up-regulation) is shown in red, and negative
(down-regulated) normalized effect size is shown in blue. Proteins were preranked by median SILAC ratio, and GSEA was performed using MySigDB C5 GO
gene set collection. Heatmap for each gene set identified is also available at https://wellslab.ucsf.edu/oncogene surfaceome. (D) MEK-dependent regulation
of protein expression induced by oncogenic transformation. Proteins shown were differentially regulated by oncogene (either log2(FC) > 1 or log2(FC) <
−1 in oncogene vs. EV) and were then reversed (flipped log2(FC) < −1 and log2(FC) > 1 in MEK inhibition vs. respective cell line) in at least three cell lines.
(E) PODXL is significantly up-regulated across various carcinoma with activating oncogenic signature in KRAS, HER2, BRAF, and EGFR (red) compared to no
mutations in these genes (gray). Activating oncogenic signature was defined as G12 or Q61 mutation in KRAS, L858 or amplification of EGFR, V600E mutation
in BRAF, or amplification of HER2. Genomic and expression data were obtained from the 17 TCGA provisional dataset with carcinoma (epithelial origin)
annotation. (F) MEK-independent regulation of protein expression induced by oncogenic transformation. Proteins shown were differentially regulated by
oncogene (either log2(FC) > 1 or log2(FC) < −1 in onco vs. EV) and were then reverted to a median level but not reversed (flipped log2(FC) < −1 and
log2(FC) > 1 in MEK inhibition vs. respective cell line) in at least three cell lines.
Combining ConA and HILIC enrichments allowed for sam-
pling of different glycan classes, and the aggregated results
of intact N-glycoproteomic analyses identified a total of
2,648 unique N-glycopeptides that passed conservative filtering
described in Materials and Methods (Fig. 4 and SI Appendix,
Fig. S12). Of this total, 189 were redundant glycan–glycosite
pairs, that is, glycoforms that resulted from miscleaved or dif-
ferentially oxidized peptides, leaving a total of 2,459 unique
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glycoforms (Fig. 4A). These glycoforms map to 785 N-glycosites
found on a total of 480 glycoproteins. Thus, on average, each
glycoprotein had 1.6 N-linked glycosites, and each site had, on
average, 3.1 different glycans, reflecting significant heterogene-
ity in glycosylation. Similar yet unique glycoforms indicated that
the heterogeneity of protein N-glycosylation is driven largely by
the biology and not artifacts of in-source fragmentation. Of the
785 experimentally detected glycosites, only 324 were previously
known or predicted to be glycoyslated in UniPort (45).
In total, we identified 142 different glycan structures. The gly-
cans can be categorized into six structural classes based on their
maturation state as they transition from ER to Golgi and then
split off to either lysosomal, granular, or cell surface destinations
(SI Appendix, Fig. S13) (46). The six glycan categories represent
a gradation of maturation from the least mature high man-
nose, to paucimannose, phosphomannose, complex/hybrid, and
finally fucosylated and sialylated (Fig. 4B). We identified 1,636
mannose glycopeptides containing any of 8 high-mannose-type
glycans and 210 were found trimmed to contain any of 9 different
paucimannose structures. The remaining 767 N-glycopeptides
had more complex glycans including: 210 complex/hybrid gly-
copeptides with 28 different structures, 314 of the sialylated class
with 54 different structures, and 226 of the fucosylated class with
42 different structures. We found only 17 phosphomannose con-
taining glycopeptides each having the same structural type that
are on proteins typically found in lysosomes (47–49). Thus, over
60% of the N-glycopeptides identified contained less mature
high mannose or paucimannose structures originating from pro-
cessing in the ER or early Golgi. It is not surprising to find
these high-mannose modifications associated with cell surface
proteins as others have seen that high-mannose N-glycosylation
is abundant at the cell surface and especially associated with
oncogene transformation (50–52). Furthermore, we have vali-
dated the expression of high-mannose glycans on the cell surface
by means of ConA lectin staining (SI Appendix, Fig. S14A). Since
CSC techniques label sialic acid, we have also shown that sialic
acid is not differentially regulated at the global level shown by
SNA lectin staining (SI Appendix, Fig. S14B).
We found significant heterogeneity in the number of different
glycan structures at any given site (Fig. 4C). Approximately 45%
of the sites were observed with only one glycan structure, but
the range of glycans on these sites was broad. Some glycosites,
such as position N-234 on aminopeptidase N (ANPEP), had up
to 39 different glycans detected. Additionally, the number of
glycosites per protein varies considerably; about 70% of the gly-
coproteins have only one site of N-glycosylation, but about 10%
have over five sites. There is a general trend between the num-
ber of glycosites identified on a given protein and the number of
unique glycans it has; however, some proteins show significantly
increased heterogeneity of glycans relative to their number of
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total glycosites (Fig. 4D). The most extreme glycan diversity was
observed on ANPEP, on which 59 unique glycans were identi-
fied across eight glycosites (Fig. 4E). Interestingly, the glycosites
with higher glycan diversity mapped to specific regions on the
three-dimensional structure of ANPEP. One face of the protein
containing a cluster of four asparagines (at positions 128, 234,
265, and 818) had high glycan diversity ranging from 19 to 39
different glycan structures per glycosite, while the opposite face
containing three clustered asparagines (at positions 625, 681, and
735) had much lower diversity, ranging between 1 and 8 differ-
ent glycan structures per site. This suggests topological bias of
glycosylation on the folded protein structure.
We next applied quantitative analysis to compare the different
oncogene-transformed cell lines in terms of their glycoproteome
landscapes and changes between them and the EV control.
We observed hundreds of glycopeptides that were significantly
and differentially expressed (q < 0.05) upon oncogenic trans-
formation relative to the EV control (SI Appendix, Fig. S15).
In general, the volcano plots were symmetric, reflecting bidi-
rectional changes, and the fold changes ranged from 50-fold
down-regulated to 50-fold up-regulated, representing significant
remodeling of the glycoproteome. Changes in glycosylation were
greater than changes in surface protein expression, which range
from twofold to eightfold (SI Appendix, Fig. S5). We quanti-
fied about 600 glycopeptides in each dataset, of which two-thirds
are shared in all datasets (Fig. 5A). There was high quantita-
tive reproducibility of the glycopeptide measurements based on
the close hierarchical clustering of the three biological repli-
cates (Fig. 5B), tight clustering by principal component analysis,
and low (<30%) median CV from the EV control cell line (SI
Appendix, Fig. S16). MEKDD and BRAFV600E had the greatest
glycoproteome similarity, while EV was the farthest removed
from all of the oncogenes.
The UpSet plot in Fig. 5C displays significant glycopeptide dif-
ferential expression that is shared and unique to each cell line.
MCF10A transformed with the KRASG12V oncogene resulted in
the largest set of uniquely changing glycopeptides; 154 of the 234
differentially expressed glycopeptides in the KRASG12V cell line
were unique to KRASG12V transformation. Some of these were
highly protein specific. For example, 28 of the 154 glycopeptides
uniquely differentially expressed by KRASG12V were identified
from ANPEP, and all were up-regulated upon oncogenic trans-
formation, as was the protein itself (SI Appendix, Fig. 17). Other
glycopeptides from ANPEP were differentially expressed in dif-
ferent sets of cell lines. In fact, 51 of 69 glycopeptides from
ANPEP were differentially expressed in at least one cell line; 12
ANPEP glycopeptides were significantly up-regulated in HER2,
and 5 were shared between HER2 and KRASG12V.
BRAFV600E, EGFRL858R, and MEKDD shared the most over-
lap of significantly changing glycopeptides between any group
of three cell lines (Fig. 5C); 24 glycopeptides belonged to
this intersection: 12 were overexpressed and 12 were underex-
pressed upon oncogenic transformation. Laminin subunit alpha-
3 (LAMA3) and N-acetylglucosamine-6-sulfatase were most
represented in the overexpressed and underexpressed group,
respectively. Four glycopeptides from each protein were iden-
tified and significantly differentially expressed in these three
cell lines. Six glycopeptides were significantly differentially
expressed across all six cell lines, three of which were identi-
fied from galectin-3 binding protein (Gal-3BP), and all were
down-regulated glycopeptides modified with high-mannose gly-
cans (SI Appendix, Fig. S18). To explore this dataset, a data
browser was made to view each individual glycopeptide identified
(https://wellslab.ucsf.edu/oncogene surfaceome).
We explored the glycan composition of differentially
expressed glycopeptides to capture a broader view of differential
glycosylation in the oncogene-transformed cell lines and to
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(A) An UpSet plot shows glycopeptide identifications that are unique to or
shared between datasets. (B) Pairwise Pearson correlations from all replicate
analyses illustrate clustering between MEKDD and BRAFV600E glycoproteome.
(C) An UpSet plot displays the shared and unique glycopeptides that are sig-
nificantly differentially expressed upon oncogenic transformation (q< 0.05)
as assessed by linear models for microarray data (LIMMA) with Bonferroni-
adjusted P values. (D) A heatmap displays the differences in glycan type
distribution for up- and down-regulated glycopeptides across cell lines.
see whether general trends emerged. The heatmap in Fig. 5D
displays the differential glycome composition of glycopeptides
changing more than twofold upon oncogenic transformation
compared to EV control. We, again, observe greatest sim-
ilarity between BRAFV600E, EGFRL858R, and MEKDD cell
lines, which have an increased proportion of high-mannose
glycans in up-regulated glycopeptides. In contrast, HER2
and KRASG12V expressed fewer up-regulated high-mannose-
modified glycopeptides and showed an increased proportion
of complex/hybrid-type glycopeptides. Further inspection re-
vealed that nearly all of the up-regulated glycopeptides with
a complex/hybrid glycan from the cell lines harboring HER2
(12 of 12) and KRASG12V (13 of 18) mapped to ANPEP. This
protein was also up-regulated on the KRASG12V surfaceome
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(6), displayed the highest degree of glycan heterogeneity within
the glycoproteomic data, and has previously been implicated in
tumorigenesis (53, 54).
Discussion
Oncogenesis is a complex phenomenon that involves aberrant
changes in multiple biological processes to promote cancer cell
survival (1). Here we study how the surfaceome remodels in
a simplified cell autologous model by six prevalent and neigh-
boring oncogenes that drive proliferation through the MAPK
signaling node. Genetic studies have shown that these onco-
genes typically exhibit mutual exclusivity in tumors from can-
cer patients (9). The surfaceome is a terminal manifestation
of these signaling pathways. We find significant differences in
detailed expression patterns, consistent with previously reported
differences in feedback loops and collateral signaling pathways
between these oncogenes (55). However, we find that these
oncogene-induced surfaceome differences harmonize in simi-
lar functional outcomes overall, and consistent with observed
mutual exclusivity.
We took a reductionist approach, starting from an immor-
talized epithelial cell line stably transformed with each of the
six different oncogenes to determine how the surfaceome is
remodeled in a cell autologous fashion. This system is clearly
an approximation and does not recapitulate the complexity of
tumors that vary in cellular context, genetic variation, hetero-
geneity, oncogene expression, the presence of host immune,
and metabolism. Nonetheless, cell culture models are a prac-
tical reality allowing isogenic comparison between oncogenes,
renewable access to materials that permits studies to be readily
reproduced (56–58). We chose the spontaneously immortalized
breast epithelial cell line, MCF10A, where the functional loss
of p16INK4a allows cells to be cultured with a myriad of onco-
genes without oncogene-induced senescence. We picked this
over cancer cell lines which are already transformed or other
artificially immortalized cell lines, because they often contain
genetic lesions that may cause genomic instability, leading to a
more idiosyncratic background. Overall, we find that indepen-
dent expression of each of these six oncogenes induced profound
changes in the surfaceome, both in the proteins expressed and
the glycans that decorate them.
Common Phenotypes and Biological Themes Induced by the Six
Oncogenes. Although the six oncogenes we studied (HER2 over-
expression, EGFRL858R, KRASG12V, BRAFV600E, MEKDD, and
AKTmyr) have many variants that could have different pheno-
types, we chose well-known representatives, to begin to under-
stand the similarities and differences between them at a coarse-
grain level. Transformation with each of these oncogenes led to
rapid growth, to varying degrees, in the absence of growth factors
and produced somewhat different cell morphologies character-
istic of a cancer cell transformed phenotype. Each oncogene
caused large changes in the surfaceome, where about 40% of the
detected N-glycoproteins had altered expression level by more
than twofold, evenly divided between up- and down-regulated
proteins, reflecting bidirectional cell surface remodeling.
There were important differences between the oncogenes,
and they clustered into two groups based on growth rates, sur-
faceomes and associated glycans. Cluster 1, containing HER2
overexpression and KRASG12V, was most aggressive in prolifer-
ation and reduced adhesion. Cluster 2 was less aggressive, and
included EGFRL858R, BRAFV600E, MEKDD, and AKTmyr. We
believe much of the similarity between HER2 and KRAS derives
from KRAS-induced expression of HER2, whereas EGFR sup-
presses expression of HER2, probably reflecting their signaling
redundancy. MCF10A is derived from normal breast epithe-
lial cells, and, among these oncogenes, HER2 overexpression
is most commonly seen in breast cancer patients, at 13% com-
pared to 2% for KRAS, 2.8% for EGFR, 5% for AKT1, 1.7%
for BRAF, and 0.6% for MEK1 (SI Appendix, Fig. S19). Each
of these also shows remarkable mutual exclusivity relative to
the others in breast cancer patients, reflecting oncogene func-
tional redundancies. Further in silico comparison of oncogenic
mutational occurrence across all cancer types (59, 60) indicates a
strong mutual exclusivity between BRAF and KRAS, and a slight
mutual exclusivity with EGFR (SI Appendix, Fig. S20).
Alterations in Transporter Expression. One of the most pro-
nounced oncogene-induced changes we observed is to proteins
involved in solute transport that reverse upon MEK inhibi-
tion, including up-regulation of SLC2A1, SLC6A15, SLC7A1,
SLCO4A1, and MF12/melanotransferrin, and down-regulation
of SLC22A5 and STEAP4 (Fig. 3D). SLC6A15 acts as a pref-
erential methionine amino acid transporter and shows dramatic
up-regulation in both KRAS- and HER2-transformed cells. This
is consistent with recent studies showing that KRAS-transformed
cells exhibit an extreme sensitivity to methionine deprivation
(61). The Warburg Effect preferentially shifts cancer cells toward
glycolysis, thereby promoting accelerated growth and division
(62). We find that SLC2A1, also known as glucose transporter-
1, is significantly up-regulated in all oncogene-transformed cells,
which would facilitate anaerobic glycolysis and increased growth
for these cells. Our data show up-regulation of SLCO4A1, a part
of the organic anion transporter family that assists in transport-
ing hormones such as prostaglandins and vasopressin. Height-
ened expression of this hormone transporter has been previously
seen in metastatic colorectal cancer (63). SLC7A1 has been
shown to be up-regulated across many cancer types, including
colorectal cancer (64). Others have shown that SLC7A1 mes-
senger RNA expression level decreases upon MAPK pathway
inhibition (65), which is consistent with our proteomics data.
General Down-Regulation of Receptor Tyrosine Phosphatases and
Tumor Suppressors. Another important theme found within our
data is a general down-regulation of surface proteins involved
in receptor tyrosine phosphatases and other tumor suppressors
such as PTPRF, PTPRS, UNC5B, and BCAM (Figs. 2A and
3D). The expression of PTPRF and PTPRS, in particular, has
been associated with decreased metastasis through the inactiva-
tion of EGFR signaling, emphasizing their importance as tumor
suppressor proteins in numerous cancer contexts (66, 67). Both
of these proteins show a marked decrease in expression across
the majority of the oncogene-transformed cells, perhaps as a
means to promote growth and metastasis. Similarly, UNC5B has
recently been shown to halt tumor progression in an in vivo
model of bladder cancer, through inducing cell cycle arrest in
the G2/M phase (68). Lastly, BCAM has been previously shown
to be a tumor suppressor in a model of hepatocellular carcinoma
(69), and decreased expression in all oncogene-transformed cells
may signify the removal of tumor-suppressive signaling.
Alteration in Adhesion Molecules. Metastasis is the leading cause
of death for patients with cancer, and tumor cells acquire the
ability to penetrate the surrounding tissues, thus leading to inva-
sion (70). Many of these acquired functionalities are through
changes in adhesion molecules on the cell surface, which play
the role of mediating cell–cell interactions. Within our dataset,
we identified five targets, LAMC2, LAMA3, LAMB3, PODXL,
and MME, that are known to play important roles in mediat-
ing metastasis in various tumor types and we find to be up-
regulated across the majority of oncogenic mutants (Figs. 2A and
3D). LAMC2 has previously been shown to promote epithelial–
mesenchymal transition [EMT] and invasion in an in vivo model
of lung adenocarcinoma (71). It has also been shown that col-
orectal cancer with high MAPK activity expresses heightened
levels of LAMC2, supporting our proteomic results that show
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reversal upon MEK inhibition (72). PODXL had increased
expression in all six mutant cell lines, and has been implicated
in increasing the aggressiveness of breast and prostate cancer
through the induction of both MAPK and PI3K signaling (73).
PODXL is also a glycoprotein with extensive mucin-type O-
glycosylation, the overexpression of which can lead to increased
metastatic potential through increased cell cycle progression via
the PI3K and MAPK axes (74–76). MME, known as neprilysin,
was found up-regulated in all six oncogenic mutants compared to
the EV control. While the function of MME has not been stud-
ied in great detail, it is considered to be an adverse prognostic
marker for patients with lung adenocarcinoma (77) and has been
found to play an important role in the growth and progression
of colorectal cancers (78). MME was also found significantly up-
regulated in surfaceomics studies of isogenic cells expressing the
tubular sclerosis gene associated with bladder cancer (79). Inter-
estingly, MME is up-regulated across all oncogenes in both the
oncogene and MEKi datasets, suggesting that MME expression
is not regulated through the MAPK or PI3K axis. This height-
ened expression of MME in all oncogenic contexts presents an
opportunity for future research into synthetic lethality studies
with MME inhibition in combination with MEKi or other MAPK
targets.
Immune Modulation. Another prominent cause of cancer pro-
gression is the evasion of immune surveillance. This can be
achieved by overexpressing proteins that have a net immuno-
suppressive effect or by down-regulating proteins that increase
immune activation. Here, we identified three differentially reg-
ulated proteins, NT5E, HLA-F, and DSE, that play important
roles in immune functions (Fig. 3D). NT5E, which was up-
regulated in all the proliferative oncogene cell lines, promotes
immunosuppression through the production of adenosine from
AMP, which can decrease the capacity of natural killer cells
to produce immune-activating IFN molecules and prevents the
clonal expansion of cytotoxic T cells in the surrounding tumor
tissue (80). Conversely, HLA-F and DSE (also known as der-
matan sulfate epimerase) were down-regulated in all oncogene-
expressing cell lines, and both play a role in immune system
activation and tumor rejection, through activation of NK cells
or cytotoxic T cells, respectively, in the tumor microenviron-
ment (81, 82). Both NT5E and HLA-F are down-regulated upon
MEKi (Fig. 3D).
Down-Regulation by Shedding. Proteolytic cleavage of proteins
at the cell surface leads to ectodomain shedding and the exis-
tence of neo N termini. The loss of ectodomains would lead
to decreased peptide detection by LC-MS/MS. We identified
four surface proteins reduced in detection, MSLN, TACSTD2,
NRCAM, and GPC1, that are known to undergo proteolysis
to enhance the growth and metastasis of cancer (83–85). In
particular, NRCAM, which had lower surface levels in all six
oncogenic mutants, is a cell–cell adhesion molecule; it is known
to be shed by proteolysis, and the shed form stimulates cell pro-
liferation via the AKT pathway (86). Perhaps unsurprisingly,
NRCAM did not exhibit a renormalization of expression levels
after MEK inhibition, due to its exclusive function through the
AKT pathway.
Changes in Glycosylation Machinery and Protein N-glycosylation.
Alterations in glycosylation are common features of cancer
cells (35) which can result from a variety of factors, including
changes in expression of glycosyltransferases, availability of sugar
nucleotide substrates, alteration in expression of substrate pro-
teins, or changes to the tertiary structure of the protein substrate
that disrupt transfer of the glycan. We find that glycosyl trans-
ferases FUT10, EXT2, GALNT11, GCTN2, and ST6GALNAC2
are highly up-regulated across all oncogenic cell lines. FUT10
is an α-1,3-focusyltransferase, and FUTs are critical for the
production of LewisX and Sialyl LewisX antigens which are
hallmarks of invasion (87). In fact, the most aggressive of our
oncogene cell lines (HER2 and KRAS) are significantly up-
regulated in complex hybrid-type glycans for which these are
members, and especially noteworthy for ANPEP. EXT2 forms
a heterodimer with EXT1 in the Golgi functioning as a glyco-
syl transferase involved in catalyzing the formation of heparin,
a substrate that contributes to structural stability of the extra-
cellular matrix, thereby mediating processes such as adhesion,
immune infiltration, and signaling (88). Unsurprisingly, alter-
ations in heparan sulfate formation have been shown to have
emerging roles in oncogenesis, of which EXT2 is a primary facil-
itator (89). GALNT11 is a protein involved in the initiation of
mucin-type O-glycosylation, a well-known marker that is overex-
pressed in cancer (90–92). MUC-1 is also a very important drug
target for immunotherapy (93–96). Interestingly, a common sub-
strate for this family of enzymes, PODXL, is also up-regulated
across all oncogenic cell lines (see above), suggesting a possible
mechanism by which increased GALNT11 promotes progrowth
phenotypes in these cell lines. GCTN2 is a glycosyltransferase
(97), and specifically implicated in the transition from na¨ıve to
germinal center B cell (98).
ST6GalNAc2 is a sialyltransferase that catalyzes attachment of
GalNAc to core glycans and is paradoxically up-regulated in all
of the oncogene cell lines. A genome-wide short hairpin RNA
screen in mice for genes that suppress metastasis identified and
validated ST6GalNAc2 as the strongest metastasis suppressor.
ST6GalNAc2 is strongly down-regulated in estrogen receptor-
negative breast cancer tumors. Silencing of ST6GalNAc2 pro-
motes binding of Galectin-3 and retention of tumor cells to sites
of metastasis. Galectin-3 is a member of S-type lectins and a
known modulator of tumor progression (99) by enhancing aggre-
gation of tumor cells during metastasis and preventing anoikis
(100–102). Galectin-3 binds to terminal fucose on glycans of
Gal-3BP which ST6GalNAc2 blocks via sialylation (102). We
found that all glycopeptides from the eight glycosites Gal-3BP
were down-regulated up to 50-fold in all cell lines (SI Appendix,
Fig. S18).
Our glycoproteomic analyses show that protein N-
glycosylation is dramatically changed upon oncogenic trans-
formation, and that distinct genetic drivers of oncogenesis
promote unique changes to the glycoproteome. The majority of
differentially expressed glycopeptides were unique to individual
cell lines. We observed greatest similarity between BRAFV600E,
EGFRL858R, and MEKDD, which has been consistent through-
out different analyses of these cell lines (Fig. 5B). There
were significant differences between the oncogene cluster 1
(KRASG12V/HER2) and cluster 2 (EGFRL858R/BRAFV600E/
MEKDD/AKTmyr). Specifically, we found differential increase in
complex hybrid glycans and decrease in high mannose in cluster
1 and just the opposite for cluster 2.
There is abundant evidence to suggest that high-mannose-type
glycans are present at the cell surface and, furthermore, that
cancerous cells display increased abundance of high-mannose
glycans at their cell surface (52, 103). A similar observation
was reported in the glycomic comparison of transformed versus
human embryonic stem cells (hESCs), where high-mannose gly-
cans were observed at significantly higher abundance on plasma
membranes of hESCs (50). Together, these observations help to
explain the similarities between cancerous cells and hESCs, such
as the regulation of tumor suppressor genes and the ability to
self-renew (104). This is consistent with our studies, although
we cannot exclusively rule out that some of the high-mannose
glycans we observe are coming from proteins in route to the
membrane.
Our data suggest glycosylation is quite heterogeneous, possibly
reflecting incomplete maturation. The most stunning example in
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our data of heterogeneity in glycosylation was for ANPEP, an
amino peptidase also up-regulated at the protein level across
most cell lines. The most extreme example was site N234 of
ANPEP, where we found 29 different glycan structures. When
these are arranged in order of glycan maturation, we observed
a close representation of its steady-state progression through
the secretion pathway (SI Appendix, Fig. S13). ANPEP also
showed the greatest representation within complex/hybrid gly-
copeptides that were up-regulated in HER2 and KRASG12V cell
lines (Fig. 5D). ANPEP was most up-regulated in KRASG12V
in surfaceomic analyses, and its expression was not dramati-
cally influenced by MEK inhibition. ANPEP expression in our
surfaceomic and glycoproteomic data represents one way in
which KRASG12V diverges from other members of the MAPK
pathway. These data, combined with ANPEP’s previously iden-
tified role in angiogenesis (54), underscore its importance in
KRASG12V-positive tumors. ANPEP glycosylation may serve as
a very sensitive biomarker of glycan metabolism in cells, given its
highly diverse and heterogeneous patterns.
Conclusions
We provide a large-scale comparative study of how six neighbor-
ing proliferative oncogenes cause large-cell autologous remod-
eling in the surfaceome and glycoproteome. While many of the
changes are specific to given oncogenes at both the protein and
glycopeptide level, we observe common biological themes sug-
gesting functional redundancy of the specific cellular expression.
This is consistent with observations that common tumors can
express these different oncogenes, although not together. We
commonly observe up-regulation of surface proteins involved
in metabolite transport, glycosylation, and immune suppres-
sors and down-regulation of adhesion proteins and tumor sup-
pressors, which is consistent with increased cell growth and
invasion that are well-known properties of cancer cells. These
studies were deliberately conducted in isogenic cell lines to
isolate the oncogene-induced changes. Even in a simplified
autologous cell model, we recapitulate many of the hallmarks
of transformed cells driven by complex but functionally redun-
dant changes to the surfaceome. We believe the work provides
important insights into the similarities and differences among
the neighboring oncogenes and provides opportunities to pursue
antibody tools to follow in more complex tumor settings.
Data Archival. All proteomics dataset has been deposited
to ProteomeXchange Consortium (proteomecentral.
proteomexchange.org) via the PRIDE partner repository
accessible (identifier PXD017039). Interactive illustrations of
several figures are also available in a data browser (https://
wellslab.ucsf.edu/oncogene surfaceome).
SI Appendix. SI Appendix, Supplemental Materials and Methods,
Figs. S1–S20, and Description of Datasets S1 to S25 is included as
a single PDF.
Materials and Methods
All MCF10A cells were cultured according to established protocols unless
otherwise stated. Surfaceome of each oncogene-transformed cell line was
compared to EV control using SILAC-based quantification. For inhibition
study, each oncogene-transformed cell line was treated with 100 nM MEK
inhibitor PD032590 or dimethyl sulfoxide control for 3 d, and surfaceome
changes were compared in each respective cell line using SILAC-based
quantification. Glycoproteome of each oncogene-transformed cell line was
quantified using label-free quantification. Detailed materials and meth-
ods are included in SI Appendix, and supplementary data are available as
Datasets S1–25.
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